PedAM
Pediatric Disease Annotations & Medicines
| Disease | spondylolisthesis |
| Phenotype | C0029456|osteoporosis |
| Sentences | 3 |
| PubMedID- 26240717 | Methods: forty-five women with osteoporosis diagnosed with degenerative spondylolisthesis from one of the three treatment groups were evaluated based on: short-duration treatment (average, 5.5 months; n=15; daily subcutaneous injection of 20 microg teriparatide), long-duration treatment (average, 13.0 months; n=15; daily subcutaneous injection of 20 microg teriparatide), and bisphosphonate treatment (average, 13.0 months; n=15; weekly oral administration of 17.5 mg risedronate). |
| PubMedID- 22872218 | Methods: fifty-seven women with osteoporosis diagnosed with degenerative spondylolisthesis were divided into 2 treatment groups, a teriparatide group (n = 29; daily subcutaneous injection of 20 mug of teriparatide) and a bisphosphonate group (n = 28; weekly oral administration of 17.5 mg of risedronate). |
| PubMedID- 23354115 | Methods: sixty-two women with osteoporosis diagnosed with degenerative spondylolisthesis were divided into 3 groups: a teriparatide group (daily subcutaneous injection of 20 mug of teriparatide, n = 20), a bisphosphonate group (daily oral administration 2.5 mg of risedronate, n = 20), and a control group (without medication for osteoporosis, n = 22). |
Page: 1